Heart Test Laboratories, Inc. (NASDAQ:HSCS) Short Interest Update

Heart Test Laboratories, Inc. (NASDAQ:HSCS) was the recipient of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 33,300 shares, a decrease of 13.5% from the January 15th total of 38,500 shares. Based on an average daily volume of 35,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 4.1% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reaffirmed a “buy” rating and set a $12.00 target price on shares of Heart Test Laboratories in a research report on Wednesday, December 18th.

Heart Test Laboratories Price Performance

HSCS opened at $3.91 on Tuesday. Heart Test Laboratories has a 1-year low of $2.36 and a 1-year high of $18.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.52. The business has a 50 day moving average of $3.62 and a 200-day moving average of $3.44.

Heart Test Laboratories (NASDAQ:HSCS) last issued its earnings results on Monday, December 16th. The company reported ($2.27) EPS for the quarter, topping the consensus estimate of ($2.30) by $0.03. During the same period in the prior year, the firm earned ($15.92) earnings per share. On average, equities analysts expect that Heart Test Laboratories will post -10.01 EPS for the current fiscal year.

Heart Test Laboratories Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.